We describe here an innovative, non-transgenic animal model of Alzheimer's disease. This model mimics early stages of sporadic disease, which represents the vast majority of cases. The model was obtained by interfering with the complex between a disintegrin and metalloproteinase domain containing protein 10 (ADAM10), the main α-secretase candidate, and its partner, synapse-associated protein 97, a protein of the postsynaptic density-membrane associated guanylate kinase family. Association of ADAM10 with synapse-associated protein 97 governs enzyme trafficking and activity at synapses. Interfering with the ADAM10/synapse-associated protein 97 complex for 2 weeks by means of a cell-permeable peptide strategy is sufficient to shift the metabolism of the amyloid precursor protein towards amyloidogenesis and allows the reproduction of initial phases of sporadic Alzheimer's disease. After 2 weeks of treatment, we detected progressive Alzheimer's disease-like neuropathology, with an increase of β-amyloid aggregate production and of tau hyperphosphorylation, and a selective alteration of N-methyl-d-aspartic acid receptor subunit composition in the postsynaptic compartment of mouse brain. Behavioural and electrophysiological deficits were also induced by peptide treatment

Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease / R. Epis, E. Marcello, F. Gardoni, C. Vastagh, M. Malinverno, C. Balducci, A. Colombo, B. Borroni, H. Vara, M. Dell'Agli, F. Cattabeni, M. Giustetto, T. Borsello, G. Forloni, A. Padovani, M. Di Luca. - In: BRAIN. - ISSN 0006-8950. - 133:11(2010 Nov), pp. 3323-3335. [10.1093/brain/awq217]

Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease

R. Epis;E. Marcello;F. Gardoni;M. Malinverno;M. Dell'Agli;F. Cattabeni;T. Borsello;M. Di Luca
2010-11

Abstract

We describe here an innovative, non-transgenic animal model of Alzheimer's disease. This model mimics early stages of sporadic disease, which represents the vast majority of cases. The model was obtained by interfering with the complex between a disintegrin and metalloproteinase domain containing protein 10 (ADAM10), the main α-secretase candidate, and its partner, synapse-associated protein 97, a protein of the postsynaptic density-membrane associated guanylate kinase family. Association of ADAM10 with synapse-associated protein 97 governs enzyme trafficking and activity at synapses. Interfering with the ADAM10/synapse-associated protein 97 complex for 2 weeks by means of a cell-permeable peptide strategy is sufficient to shift the metabolism of the amyloid precursor protein towards amyloidogenesis and allows the reproduction of initial phases of sporadic Alzheimer's disease. After 2 weeks of treatment, we detected progressive Alzheimer's disease-like neuropathology, with an increase of β-amyloid aggregate production and of tau hyperphosphorylation, and a selective alteration of N-methyl-d-aspartic acid receptor subunit composition in the postsynaptic compartment of mouse brain. Behavioural and electrophysiological deficits were also induced by peptide treatment
amyloid precursor protein metabolism; animal models; NMDA; SAP97; synaptopathy
Settore BIO/14 - Farmacologia
Settore BIO/16 - Anatomia Umana
Article (author)
File in questo prodotto:
File Dimensione Formato  
Epis.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 589.69 kB
Formato Adobe PDF
589.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
awq217.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 592.55 kB
Formato Adobe PDF
592.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/154364
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 57
social impact